Mass Balance and Biotransformation of [14C]HSK7653 in Human

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

January 21, 2021

Conditions

Type II Diabetes

Interventions

DRUG

[14C]HSK7653

25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.

Trial Locations (1)

the First Affilicated Hospital of Soochow University, Suzhou

All Listed Sponsors

collaborator

First Affiliated Hospital of Suzhou Medical College

OTHER

lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04540016 - Mass Balance and Biotransformation of [14C]HSK7653 in Human | Biotech Hunter | Biotech Hunter